These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29563895)

  • 1. Novel Somatostatin Receptor Ligands Therapies for Acromegaly.
    Paragliola RM; Salvatori R
    Front Endocrinol (Lausanne); 2018; 9():78. PubMed ID: 29563895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL
    Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).
    Brunetti A; Antonini S; Saladino A; Lavezzi E; Zampetti B; Cozzi R
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor ligands in the treatment of acromegaly.
    Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
    Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for acromegaly: future role for pasireotide?
    Ben-Shlomo A
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic agents for acromegaly.
    Melmed S
    Nat Rev Endocrinol; 2016 Feb; 12(2):90-8. PubMed ID: 26610414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide-Resistant Acromegaly: Challenges and Solutions.
    Corica G; Ceraudo M; Campana C; Nista F; Cocchiara F; Boschetti M; Zona G; Criminelli D; Ferone D; Gatto F
    Ther Clin Risk Manag; 2020; 16():379-391. PubMed ID: 32440136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New medical therapies on the horizon: oral octreotide.
    Biermasz NR
    Pituitary; 2017 Feb; 20(1):149-153. PubMed ID: 28091879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
    Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for acromegaly.
    Störmann S; Schopohl J
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):79-97. PubMed ID: 24400774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasireotide in Acromegaly: A Review.
    McKeage K
    Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational therapies for acromegaly.
    Grasso LF; Pivonello R; Colao A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the pharmacotherapy of patients with acromegaly.
    Fleseriu M
    Discov Med; 2014 Jun; 17(96):329-38. PubMed ID: 24979253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.